No Data
No Data
Express News | Cantor Fitzgerald Reiterates Overweight on Zevra Therapeutics
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $20
Zevra Therapeutics Analyst Ratings
Buy Rating Reaffirmed for Zevra Therapeutics Amidst Unjustified Market Reaction and Strong Drug Prospects
Zevra Therapeutics, Inc. (NASDAQ:ZVRA): Is Breakeven Near?
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Raises Target Price to $25